国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (3): 204-206.doi: 10.3760/cma.j.issn.1673422X.2016.03.011

• 综述 • 上一篇    下一篇

分化型甲状腺癌碘拮抗相关基因研究进展

俞云芳,葛明华   

  1. 215000 苏州大学医学部（俞云芳）；浙江省肿瘤医院头颈外科（葛明华）
  • 出版日期:2016-03-08 发布日期:2016-02-03
  • 通讯作者: 葛明华，Email： gemingh@163.com E-mail: gemingh@163.com
  • 基金资助:

     浙江省医药卫生科技计划（2015DTA003）； 国家高技术研究发展计划（863计划）子项目（03-GZ-YX-001）

Advance of radioiodine antagonist related gene of differentiated thyroid carcinoma

Yu Yunfang, Ge Minghua   

  1. Medical Department of Soochow University, Suzhou 215000, China
  • Online:2016-03-08 Published:2016-02-03
  • Contact: Ge Minghua, Email: gemingh@163.com E-mail: gemingh@163.com
  • Supported by:

    Medical and Health Platform Program of Zhejiang Province of China (2015DTA003); Subproject of National High Technology Research and Development Program of China (863 Program) (03-GZ-YX-001)

PDF

1338

摘要： 甲状腺癌是最常见的内分泌系统恶性肿瘤，其中分化型甲状腺癌占多数，后者的主要治疗手段有手术治疗、术后碘放射性同位素（131I）治疗和促甲状腺激素抑制治疗等。131I在分化型甲状腺癌的诊断与治疗中有较为广泛的应用，然而，一部分分化型甲状腺癌患者因钠-碘转运体基因、BRAF基因、双链复合蛋白8、微小RNA、细胞角蛋白19等基因的改变而降低或丧失对131I的摄取能力。这些基因在分化型甲状腺癌的治疗中尤为重要，可作为肿瘤治疗疗效评估的重要指标。

关键词: 甲状腺肿瘤, 碘放射性同位素, 基因

Abstract: Thyroid carcinomas are the most common endocrine malignancies, and the overwhelming majority of them is differentiated thyroid carcinoma (DTC). The major therapies of DTCs are surgical resection, thyroid stimulating hormone (TSH) inhibitory treatment and iodine radioisotope (131I) treatment. 131I has been widely applied for the diagnosis and treatment of DTC, however, part of these patients may reduce or loss the uptake capacity of  131I owing to the alteration of sodium-iodide symporter gene, BRAF, paired box 8, microRNA and cytokeratin 19. These genes are particularly important in the treatment of DTC, which can be used as biomarkers in the treatment efficacy evaluation.

Key words: Thyroid neoplasms, Iodine radioisotopes, Genes